Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.51 |
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738286 | 0.92 | CNR2 (0.61) | CNR2CNR1NPC1GAAASAH1 | |
| SCHEMBL4385751 | 0.89 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL739854 | 0.84 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL735903 | 0.84 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL4377379 | 0.83 | L3MBTL1 (0.50) | CNR2CNR1NPC1 | |
| SCHEMBL740116 | 0.75 | CNR2 (0.85) | CNR2CNR1 | |
| SCHEMBL4379407 | 0.75 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL739956 | 0.72 | CNR2 (0.49) | CNR2CNR1GAA | |
| SCHEMBL737086 | 0.71 | CNR2 (0.47) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL736667 | 0.70 | CNR2 (0.50) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885NPC1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.